Postoperative Use of Anti-TNF-α Agents in Patients with Crohn's Disease and Risk of Reoperation-A Nationwide Cohort Study

Inflammatory Bowel Diseases

Volumn 22, Issue 3, 2016, Pages 599-606

  Kjeldsen, Jens ^a   Nielsen, Jan ^b   Larsen, Michael Due ^b   Qvist, Niels ^b   Nørgård, Bente Mertz ^b  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

anti TNF agents; Crohn's disease; epidemiology; inflammatory bowel disease; surgery

Indexed keywords

MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR;

ADOLESCENT; ADULT; ANTAGONISTS AND INHIBITORS; COHORT ANALYSIS; CROHN DISEASE; FEMALE; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; POSTOPERATIVE CARE; PROGNOSIS; REOPERATION; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; COHORT STUDIES; CROHN DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE CARE; PROGNOSIS; REOPERATION; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84959323033     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000647     Document Type: Article

References (33)

1. Bernell O, Lapidus A, Hellers G. Risk factors for surgery and postoperative recurrence in Crohn's disease. Ann Surg. 2000;231:38-45.
2. Bernell O, Lapidus A, Hellers G. Recurrence after colectomy in Crohn's colitis. Dis colon Rectum. 2001;44:647-654; discussion 54.
3. Solberg IC, Vatn MH, Hoie O, et al. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol. 2007;5:1430-1438.
4. Rutgeerts P, Geboes K, Vantrappen G, et al. Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery. Gut. 1984;25:665-672.
5. Williams JG, Wong WD, Rothenberger DA, et al. Recurrence of Crohn's disease after resection. Br J Surg. 1991;78:10-19.
6. Olaison G, Smedh K, Sjodahl R. Natural course of Crohn's disease after ileocolic resection: endoscopically visualised ileal ulcers preceding symptoms. Gut. 1992;33:331-335.
7. Jones GR, Kennedy NA, Lees CW, et al. Systematic review: the use of thiopurines or anti-TNF in post-operative Crohn's disease maintenance-progress and prospects. Aliment Pharmacol Ther. 2014;39:1253-1265.
8. Rutgeerts P, Hiele M, Geboes K, et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology. 1995;108:1617-1621.
9. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353: 2462-2476.
10. Yang Z, Ye X, Wu Q, et al. A network meta-analysis on the efficacy of 5-aminosalicylates, immunomodulators and biologics for the prevention of postoperative recurrence in Crohn's disease. Int J Surg. 2014;12: 516-522.
11. Cosnes J, Nion-Larmurier I, Beaugerie L, et al. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut. 2005;54:237-241.
12. Lakatos PL, Golovics PA, David G, et al. Has there been a change in the natural history of Crohn's disease Surgical rates and medical management in a population-based inception cohort from Western Hungary between 1977-2009. Am J Gastroenterol. 2012;107:579-588.
13. Ramadas AV, Gunesh S, Thomas GA, et al. Natural history of Crohn's disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates. Gut. 2010;59: 1200-1206.
14. Rungoe C, Langholz E, Andersson M, et al. Changes in medical treatment and surgery rates in inflammatory bowel disease: a nationwide cohort study 1979-2011. Gut. 2014;63:1607-1616.
15. Bernstein CN, Loftus EV Jr, Ng SC, et al. Hospitalisations and surgery in Crohn's disease. Gut. 2012;61:622-629.
16. Jess T, Riis L, Vind I, et al. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark. Inflamm Bowel Dis. 2007;13:481-489.
17. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology. 2004;126:402-413.
18. Feagan BG, Panaccione R, Sandborn WJ, et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology. 2008;135:1493-1499.
19. Regueiro M, Kip KE, Baidoo L, et al. Postoperative therapy with infliximab prevents long-term Crohn's disease recurrence. Clin Gastroenterol Hepatol. 2014;12:1494-1502.e1.
20. Aguas M, Bastida G, Cerrillo E, et al. Adalimumab in prevention of postoperative recurrence of Crohn's disease in high-risk patients. World J Gastroenterol. 2012;18:4391-4398.
21. Pedersen CB, Gotzsche H, Moller JO, et al. The Danish Civil Registration System. A cohort of eight million persons. Dan Med Bull. 2006;53:441-449.
22. Andersen TF, Madsen M, Jorgensen J, et al. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull. 1999;46:263-268.
23. Theede K, Dahlerup JF, Fallingborg J, et al. Biologic therapy in inflammatory bowel disease. Dan Med J. 2013;60:B4652.
24. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
25. Regueiro M, Schraut W, Baidoo L, et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology. 2009;136: 441-450.e1; quiz 716.
26. Fonager K, Sorensen HT, Rasmussen SN, et al. Assessment of the diagnoses of Crohn's disease and ulcerative colitis in a Danish hospital information system. Scand J Gastroenterol. 1996;31:154-159.
27. Harboe KM, Bardram L. Nationwide quality improvement of cholecystectomy: results from a national database. Int J Qual Health Care. 2011; 23:565-573.
28. Ottesen M. Validity of the registration and reporting of vaginal prolapse surgery [in Danish]. Ugeskr Laeger. 2009;171:404-408.
29. Utzon J, Olsen PS, Bay-Nielsen M, et al. Evaluation of surgical interventions in Denmark [in Danish]. Ugeskr Laeger. 2001;163:5662-5664.
30. Moller C, Kehlet H, Utzon J, et al. Hysterectomy in Denmark. An analysis of postoperative hospitalization, morbidity and readmission [in Danish]. Ugeskr Laeger. 2002;164:4539-4545.
31. Kotze PG, Yamamoto T, Danese S, et al. Direct retrospective comparison of adalimumab and infliximab in preventing early postoperative endoscopic recurrence after ileocaecal resection for Crohn's disease: results from the MULTIPER database. J Crohn's Colitis. 2015;9:541-547.
32. Szamosi T, Banai J, Lakatos L, et al. Early azathioprine/biological therapy is associated with decreased risk for first surgery and delays time to surgery but not reoperation in both smokers and nonsmokers with Crohn's disease, while smoking decreases the risk of colectomy in ulcerative colitis. Eur J Gastroenterol Hepatol. 2010;22:872-879.
33. Vaughn BP, Moss AC. Prevention of post-operative recurrence of Crohn's disease. World J Gastroenterol. 2014;20:1147-1154.